The tyrosine kinase inhibitor (TKI) imatinib has transformed the treatment and outlook of chronic myeloid leukemia (CML); however, the development of drug resistance and the persistence of TKI-resistant stem cells remain obstacles to eradicating the disease. Inhibition of proteasome activity with bortezomib has been shown to effectively induce apoptosis in TKI-resistant cells. In this study, we show that exposure to the next generation proteasome inhibitor carfilzomib is associated with a decrease in ERK signaling and increased expression of Abelson interactor proteins 1 and 2 (ABI-1/2). We also investigate the effect of carfilzomib in models of imatinib-sensitive and -resistant CML and demonstrate a potent reduction in proliferation and induction of apoptosis in a variety of models of imatinib-resistant CML, including primitive CML stem cells. Carfilzomib acts synergistically with the TKIs imatinib and nilotinib, even in imatinib-resistant cell lines. In addition, we found that the presence of immunoproteasome subunits is associated with an increased sensitivity to carfilzomib. The present findings provide a rational basis to examine the potential of carfilzomib in combination with TKIs as a potential therapy for CML, particularly in imatinib-resistant disease.
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that arises in a hematopoietic stem cell. It is characterized by a reciprocal translocation between the long arms of chromosomes 9 and 22. The resulting fusion gene BCR-ABL, encodes a constitutively active protein tyrosine kinase Bcr-Abl, which is responsible for the pathogenesis of CML. Current first-line therapy for CML is imatinib mesylate (imatinib, Glivec; Novartis Pharmaceuticals), a small molecule tyrosine kinase inhibitor (TKI) specifically designed to inhibit the Bcr-Abl tyrosine kinase. Imatinib has dramatically improved the treatment of CML, inducing durable responses in the majority of patients with chronic phase CML. Nevertheless, two key issues remain-a number of patients develop resistance 1 and primitive CML stem cells are insensitive to imatinib. 2 The most common mechanisms of resistance are mutations in the kinase domain that affect imatinib binding, 3 BCR-ABL amplification 4 and altered drug efflux or influx. 5 Second and third generation TKIs such as dasatinib, nilotinib 6 and ponatinib 7 demonstrate clinical efficacy in some cases of imatinib resistance; however, CML stem cells remain insensitive. 8, 9 This highlights the need to find alternative therapeutic strategies to overcome resistance and eliminate the CML stem cell.
The proteasome is an enzymatic complex that has a key role in regulating cellular processes through selective degradation of intracellular proteins. There are three distinct enzymatic activities associated with the proteasome-chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L)-mediated by subunits b5, b2 and b1, respectively. Upon exposure to interferon (IFN)-g and tumor necrosis factor-a, an alternative form of the proteasome is formed, referred to as the immunoproteasome. The immunoproteasome expresses subunits LMP7, MECL1 and LMP2 in place of b5, b2 and b1, altering the proteasome to favor the generation of antigenic peptides. 10 Over the last decade, the proteasome has emerged as a therapeutic target in hematopoietic malignancies. Bortezomib, the first-in-class proteasome inhibitor (PI) validated the proteasome as a therapeutic target and has provided significant advancement in the treatment of multiple myeloma (MM) 11 and mantle cell lymphoma. 12 Clinical benefit has also been seen with bortezomib-based combinations for nonHodgkin's lymphoma, 13 myelodysplastic syndromes 14 and acute myeloid leukemia. 15 Following bortezomib's success, there are a number of next generation PIs with improved pharmacological properties in clinical trials. The next generation compound carfilzomib is an epoxyketone-based inhibitor that binds irreversibly to the proteasome. Carfilzomib has recently been approved by the FDA for the treatment of relapsed/refractory MM and demonstrates greater efficacy and fewer side effects than bortezomib. 16, 17 A number of studies support a potential role for the use of PIs in CML. In vitro studies demonstrated that bortezomib alone and in combination with kinase inhibitors is effective in imatinib-resistant CML cells. [18] [19] [20] In addition, we have previously shown that BCR-ABL activity is associated with increased proteasome activity, and that CML cell lines are more susceptible to PIs than normal counterparts. 21 In this study, we evaluate the activity of carfilzomib alone and in combination with TKIs imatinib and nilotinib, using imatinib-sensitive and -resistant CML models. We demonstrate a downregulation of phosphorylated ERK and accumulation of Abelson interactor proteins 1 and 2 (ABI 1/2), along with induction of apoptosis and inhibition of proliferation by carfilzomib in imatinib-sensitive and -resistant cell lines and CD34 þ 38 À -enriched CML stem cells. We show that the combination of carfilzomib with imatinib or nilotinib results in synergistic effects, even in imatinib-resistant cell lines. Finally, we demonstrate that the immunoproteasome is a major constituent of the total proteasome in the majority of CML cell lines and primary CML cells and that the presence of immunoproteasome subunits is associated with an increased sensitivity to carfilzomib.
RESULTS
Effect of carfilzomib on key signaling pathways in CML Cell lines and primary cells were pulsed with carfilzomib at IC 50 doses for 1 h and returned to fresh medium for 24 h before protein lysates were prepared and immunoblot analysis was performed to determine the effect of carfilzomib on Bcr-Abl signaling pathways. Carfilzomib treatment resulted in a decrease of p-ERK by 52±11% (Po0.01), with no effect on STAT5 or PI3K signaling pathways ( Figure 1a ). We next looked at the effect of carfilzomib treatment on ABI 1/2 proteins, which have been reported to inhibit ERK activation that was induced by v-Abl. 22 ABI 1/2 proteins have been shown to be stable in normal cells but rapidly degraded via the ubiquitin-proteasome pathway in Bcr-Abl expressing cells. 23 We observed increased expression of ABI 1/2 in cells in which BCR-ABL was knocked down using siRNA and also in NBM CD34 þ 38 À -enriched cells compared with CML counterparts (Supplementary Figure 1) . Treatment with carfilzomib at IC 50 levels increased the expression of ABI 1/2 in cell lines and primary CD34 þ 38 À -enriched cells (range 2.2-6.8 fold, Figure 1b ) and this was associated with an accumulation of polyubiquitinated ABI 1/2 ( Figure 1c) . ABI 2 has been reported to be tagged for degradation by the E3 ligase TRIM32 in head and neck cancer. 24 Figure 1d demonstrates an association of ABI 2 with TRIM32 in the CML cell lines, which appears to be enhanced following treatment with carfilzomib, suggesting that TRIM32 also acts as an E3 ligase to target ABI proteins for degradation in Bcr-Abl expressing cells.
Antiproliferative and apoptotic effects of carfilzomib in models of imatinib-sensitive and -resistant CML CML cell lines were treated either continuously or pulsed for 1 h with increasing concentrations of carfilzomib (1-1000 nM) for up to 72 h. A time-and dose-dependent decrease in viability was observed in all cell lines with an IC 50 of o15 nM at 24 h cultured continuously in the presence of carfilzomib (Figure 2a) . To mimic the in vivo pharmacokinetics of carfilzomib, cell lines were pulsed for 1 h with the same concentrations of carfilzomib, followed by growth in drug-free medium for up to 72 h. This treatment also induced a time-and dose-dependent decrease in viability, although higher concentrations were required to achieve IC 50 (20-79 nM, 24 h) (Figure 2b ). Under both conditions, imatinibresistant cell lines displayed equal or greater sensitivity to carfilzomib as their imatinib-sensitive counterparts. CD34 þ 38 À cells were enriched from three CML patient samples and normal bone marrow (NBM). As numbers of this enriched cell population are small, cells were exposed to a median dose of 50 nM carfilzomib for 1 h before being transferred to drugfree medium. After 24 h, the viability of CML CD34 þ 38 À cells was reduced by 39 ± 1 % compared with 19 ± 2 % in NBM (P ¼ 0.02; Figure 2c ). To assess the effect of carfilzomib on longer-term stem cell proliferation, CD34 þ cells were enriched from CML (n ¼ 3) and NBM samples (n ¼ 2), pulsed for 1 h with 50 nM carfilzomib and transferred to LTC-IC assays. Colony formation was reduced by 58±11% in CML stem cells compared with 44±7% in normal stem cells (P ¼ 0.04; Figure 2d ).
The effect of 1-h exposure to carfilzomib on the induction of apoptosis in CML cell lines and primary samples was investigated. Pulse treatment with carfilzomib at IC 50 doses induced an increase in caspase-3 activity along with an associated increase in the number of sub G0/G1 events, indicative of apoptosis (Supplementary Figure 2) . Further analysis demonstrated induction of apoptosis through both the caspase-8 and -9 pathways, consistent with previous reports (Figure 2e ). 25 Synergistic activity of carfilzomib with TKIs imatinib and nilotinib The combination of carfilzomib and imatinib or nilotinib was assessed in imatinib-sensitive and -resistant cell lines. Combinations were set up with all drugs using IC 12.5 , IC 25 , IC 50 and IC 75 values for imatinib-sensitive cell lines and drugs were combined in three ways: (i) carfilzomib and imatinib/nilotinib were added to cells simultaneously; (ii) cells were treated with carfilzomib at t ¼ 0 h, followed by imatinib/nilotinib at t ¼ 24 h; (iii) cells were treated with imatinib/nilotinib at t ¼ 0 h, followed by carfilzomib at t ¼ 24 h. Proliferation was assessed 48 h after first drug treatment. Calcusyn software was used to calculate a combination index (CI), whereby a value less than, equal to or greater than 1 indicates synergy, additivity or antagonism, respectively.
In imatinib-sensitive cell lines, all combinations of carfilzomib with the TKIs significantly reduced cell viability and proliferation compared with either drug alone (Po0.05) and were found to be synergistic (CI 0.241-0.941; IC 50 values). There was no significant difference dependent on the order in which the drugs were added or the TKI used. To assess synergy in imatinib-resistant cell lines, IC 50 values derived for the TKIs in imatinib-sensitive cell lines were used. Both, the simultaneous combination of carfilzomib and a TKI and the addition of either TKI before carfilzomib resulted in antagonistic effects (CI 1.053-4.553; IC 50 ). Pretreatment with carfilzomib for 24 h followed by addition of a TKI resulted in a significant reduction in viability and proliferation compared with carfilzomib alone in 4 out of 5 imatinib-resistant cell lines (Pp0.04; P ¼ 0.06 for Ba/F3 H396P cells) and synergy in all imatinib-resistant cell lines (CI 0.609-0.895; IC 50 ). Using p-CRKL as a marker of Bcr-Abl kinase activity, we show that the sequential combination of carfilzomib and a TKI had no effect on p-CRKL, therefore demonstrating that the synergy observed is independent of BcrAbl inhibition (Figure 3c We next investigated if the combination of carfilzomib and a TKI demonstrated a beneficial effect in CML cells. CD34 þ cells were enriched from primary CML samples (n ¼ 3) and treated as follows: 50 nM carfilzomib, 1 mM imatinib or 30 nM nilotinib used as single agents, or carfilzomib combined simultaneously and sequentially at the prior indicated concentrations. Cells treated with single agent or combined simultaneously were exposed to inhibitors for 24 h; for sequential treatment the cells were exposed to carfilzomib for 24 h followed by either TKI for 24 h. LTC-IC assays were then performed on all cell treatments. No further decrease in colony formation was observed when carfilzomib was combined simultaneously with either TKI, compared with carfilzomib as a single agent. A reduction in colony formation from 42% with carfilzomib treatment alone, to 35%, and 40% of control following sequential treatment with imatinib and nilotinib was observed ( Figure 3d) ; however, the difference was not significant (P ¼ 0.06 and P ¼ 0.19, respectively).
Proteasome profiles and subunit selectivity of carfilzomib in CML Carfilzomib has been demonstrated to primarily target CT-L subunits of both the constitutive proteasome (b5) and immunoproteasome (LMP7) in MM and lymphoma cells. 26, 27 To evaluate the inhibitory effect of carfilzomib in CML cells, we quantified the levels of constitutive proteasome and immunoproteasome subunits in primary CML cells, normal mononuclear cells and imatinib-sensitive and -resistant CML cell lines (Supplementary  Table 2 ). In primary cells, the amount of active proteasome subunits per total protein concentration was significantly higher in CML cells compared with normal donors (24.05±1.38 ng/mg vs 16.69±2.86 ng/mg, P ¼ 0.001), consistent with our previous observations that Bcr-Abl activity is associated with increased proteasome activity. 21 We found that immunoproteasome subunits were the major constituent of total proteasome in primary cells (59.1-65.4%) and Ba/F3 cell lines (61.1-70.2%), and comprised 16.3-30.1% of total proteasome in KCL22-S and -R and LAMA84-S and -R CML cell lines (Table 1) . This is in agreement with previous reports on cells of hematopoietic origin 27, 28 and confirms that the immunoproteasome is a substantive component of total proteasome in myeloid as well as lymphoid cells. The amount of CT-L subunits relative to total cellular protein was similar across all cell lines and primary CML cells (6.29±1.04 ng/mg). LMP7 was the predominant form of CT-L subunit expressed in normal mononuclear cells (83.8%), CML mononuclear cells (76.6%) and Ba/F3 cell lines (52.6-65.8%), and accounted for a significant proportion of CT-L activity in human CML cell lines (36.6-51.2%) (Figure 4a ). In keeping with previous observations, we found that primary CML cells and KCL22-S and -R and LAMA84-S and -R predominantly express the immunoproteasome subunit LMP7 (12-25.3%) relative to MECL1 (2.2-15.2%) and LMP2 (1.2-18.6%). 26 The contribution of individual proteasome subunits in Ba/F3 cell lines differs quite markedly from both primary cells and human CML cell lines. We have previously demonstrated that the proteasome subunit profiles are cell type dependent 29 and this difference may reflect the different lineage origin and species of the cell lines.
To examine the effect of carfilzomib on individual proteasome activities, cell lines were pulsed with increasing concentrations of carfilzomib (1-1000 nM) for 1 h and analyzed using the ProCISE assay. Whereas there was a dose-dependent inhibition of all proteasome activities (Figures 4b-d) , carfilzomib displayed preferential inhibitory activity against CT-L subunits, with IC 50 values of p8.32 nM for the b5 subunit and p16.55 nM for LMP7. IC 50 values for T-L and C-L subunits were at least threefold higher (Supplementary Table 3 ). 
þ cells were exposed to 50 nM carfilzomib followed by long-term culture in LTC-IC assays. Results are expressed as percentage of control colony count and represent mean±s.d. There was significantly less colony growth in CML LTC-IC compared with NBM (P ¼ 0.04). (e) Western blot analysis for activated (cleaved) caspase-8 and caspase-9 following exposure to carfilzomib.
The presence of immunoproteasome subunits increases sensitivity to carfilzomib We, along with others, have reported that the sensitivity of tumor cells to PIs may be associated with differential expression of proteasome subunits. [28] [29] [30] In this study, we found that in contrast to the proteasome profiles observed for CML cell lines and primary samples above, immunoproteasome subunits made little or no contribution to the overall proteasome activity in K562 cells (Supplementary Table 2 ). In this regard, the K562 cell line is more similar to a nonhematopoietic cell line. We demonstrate that although carfilzomib is a potent inhibitor of the b5 CT-L subunit in K562 cells (IC 50 ¼ 6.68 nM; Supplementary Table 2), the IC 50 value for carfilzomib in reducing the proliferation of this cell line was 4fivefold higher than the corresponding values for the other CML cell lines. We therefore sought to investigate whether the difference in sensitivity we observed with K562 cells was related to immunoproteasome expression. A549 lung carcinoma cell line, known to express low amounts of immunoproteasome, 26 was included as a comparison. K562 and A549 cells were cultured in the presence of 100 U/ml IFN-g for 72 h to induce Figure 4C) . The increase in LMP7 expression corresponded with Figure 4) was associated with a significant decrease in sensitivity to carfilzomib; the IC 50 value for KCL22S cells increased from 5 nM to 16 nM (P ¼ 0.01) and LAMA84S cells increased from 7 nM to 20 nM (P ¼ 0.04). These results demonstrate that the presence of both the b5 and LMP7 CT-L subunits are required for optimal effect with carfilzomib and pretreatment with IFN-g can sensitize cells to carfilzomib.
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DISCUSSION
Although the introduction of TKIs into the clinic has provided a major advancement in the treatment of CML, the development of drug resistance and persistence of TKI-resistant stem cells remain obstacles to eradicating the disease. The proteasome has become a validated target for cancer therapy, particularly in hematological malignancies.
A number of reports demonstrate that bortezomib induces apoptosis in BCR-ABL expressing cells, including those resistant to imatinib and suggest that PIs may have significant activity in CML. [18] [19] [20] 31 To date, only one study has investigated the clinical activity of bortezomib in CML. The pilot study demonstrated minimal efficacy of bortezomib as a single agent in imatinib-refractory CML and suggested that future trials should focus on alternative use of PIs in CML, such as combination-based treatments. 32 In support of this, a recent report by Dewer et al.,
31
demonstrates that a bortezomib-based regimen resulted in a complete hematological, cytogenetic and molecular remission in BCR-ABL þ acute lymphoblastic leukemia. Until recently, bortezomib was the only PI licensed for use in the clinic and its use can be restricted by limiting side effects such as peripheral neuropathy. 17 However, the next generation PI carfilzomib has received FDA approval for the treatment of relapsed/refractory myeloma and appears to exhibit less toxicities than bortezomib. In this study, we have analyzed the effect of carfilzomib, both on its own and in combination with TKIs, in cell lines that reflect a wide spectrum of imatinib resistance and in CD34 þ 38 À populations, which represent the TKI-resistant stem cell population.
Bcr-Abl activates multiple downstream signaling pathways, including ERK, PI3K and STAT5 pathways, which contribute to leukemic cell proliferation and survival. We analyzed the effect of carfilzomib on these signaling pathways and found that exposure to carfilzomib resulted in a downregulation of phosphorylated ERK; this effect was replicated across all cell line models and primary CD34 þ 38 À cells. A previous study by Orlowski et al., 33 has also suggested inhibition of ERK signaling as a key factor in proteasome inhibitor-mediated apoptosis. Following on from this, we investigated the effect of carfilzomib on ABI proteins that have been reported to negatively regulate cell growth and transformation by specifically targeting the ERK pathway. 22 ABI proteins were originally identified as binding partners of the Abl tyrosine kinase and two highly homologous members of this family, ABI-1 and ABI-2, were shown to be rapidly degraded through the ubiquitinproteasome system in Bcr-Abl-expressing cells. 23 In keeping with the findings by Dai et al., 23 we found that ABI 1/2 levels were higher in normal compared with CML CD34 þ 38 À cells and also that ABI 1/2 expression increased in CML cell lines in which BCR-ABL was knocked down. Treatment with carfilzomib resulted in a similar increase in ABI 1/2 protein expression by preventing the degradation of these proteins through the proteasome, as proved by the accumulation of polyubiquitinated ABI 1/2. ABI-2 in particular, has been documented to act as a tumor suppressor and an inhibitor of cell migration. 24, 34, 35 Kano et al., 24 demonstrated that the E3 ligase TRIM32 is responsible for mediating the degradation of ABI-2 in head and neck squamous cell carcinoma, thereby promoting tumor cell growth, metastasis and drug resistance. 34 In this study, we have demonstrated a proteinprotein interaction between ABI-2 and TRIM32 and observed an accumulation of this protein interaction following treatment with carfilzomib, suggesting that TRIM32 may also act as an E3 ligase for ABI-2 in Bcr-Abl expressing cells. The role of Bcr-Abl in promoting the degradation of ABI-2 through TRIM32 is yet to be fully delineated. Collectively, these results demonstrate a novel mechanism of action for PIs in CML. The effect of carfilzomib on the proliferation of imatinibsensitive and -resistant cell populations was evaluated using either continuous treatment, or 1-h pulse treatment, which is more reflective of the in vivo pharmacokinetics of carfilzomib. Both methods induced a time-and dose-dependent decrease in proliferation, with equal or greater sensitivity to carfilzomib exhibited by imatinib-resistant cell lines compared with their imatinib-sensitive counterparts. This is in agreement with earlier studies demonstrating that imatinib resistance does not affect sensitivity to PIs. 20, 21 The IC 50 values obtained for carfilzomib in CML cell lines are comparable to those reported for MM cell lines, 22 suggesting that these doses may be clinically relevant. Heaney et al., 20 previously demonstrated that primitive CML stem cells are sensitive to the apoptotic effects of bortezomib. Here we also demonstrate an antiproliferative and apoptotic effect of carfilzomib on the imatinib-resistant stem cell population. Furthermore, we found that the stem cells enriched from CML samples displayed greater sensitivity to carfilzomib than those enriched from nonmalignant samples.
Having established an effect for carfilzomib as a single agent in cell line models of imatinib-sensitive and -resistant CML, we also looked at the effect of carfilzomib in combination with the TKIs imatinib and nilotinib. In imatinib-sensitive cell lines, all combinations of carfilzomib with either TKI resulted in synergistic effects. Notably, we also observed that pretreatment with carfilzomib sensitizes imatinib-resistant cells to TKIs. The mechanism behind this synergistic effect is unclear; however, we demonstrate that it is independent of Bcr-Abl activity. Similar effects have been documented in a number of other studies using inhibitors of signaling pathways downstream of Bcr-Abl. For example, the combination of imatinib with chemotherapeutic agents, 36 a Hsp90 inhibitor, 37 PDK-1 inhibitor 38 and leptomycin B 39 have all been shown to produce synergistic activity in imatinib-resistant cell lines. The synergism between carfilzomib and TKIs was not replicated in the CML-quiescent stem cell population, nonetheless carfilzomib has a significant effect as a single agent in these cells.
Total levels of proteasome activity were found to be significantly higher in primary CML cells compared with normal, supporting previous observations by our group and others that demonstrate an increase in proteasome activity in BCR-ABL þ cells. 21, 32, 40 Primary cells and cell lines exhibited both constitutive proteasome and immunoproteasome subunits. Primary cells were found to express a higher percentage of the LMP7 subunit than CML cell lines. This pattern of higher immunoproteasome activity in primary cells has also been observed in MM. 26 Carfilzomib has been reported to selectively inhibit the CT-L subunits (b5 and LMP7) of the proteasome in MM and lymphoma cells. 26, 27 In keeping with this, we show that carfilzomib inhibits CT-L subunits with at least threefold selectivity compared with T-L and C-L subunits.
Finally, we investigated whether the presence of immunoproteasome subunits in CML cells influences the sensitivity of the cells to carfilzomib. Our group, along with others, have reported that sensitivity of tumor cells to PIs is associated with proteasome activity levels and subunit composition. [28] [29] [30] In addition, Parlati et al., 26 demonstrated that inhibition of either the b5 or LMP7 subunit alone was insufficient to produce an antitumor response in hematopoietic cells. In this study, we found that the CML cell line K562 exhibited little to no immunoproteasome activity and, although carfilzomib was a potent inhibitor of the b5 subunit in these cells, the IC 50 for carfilzomib in K562 cells was 4fivefold higher than that for the immunoproteasome-expressing cell lines. Induction of immunoproteasome expression in K562 cells by IFN-g resulted in an increase in sensitivity to carfilzomib, and this effect was also replicated in the lung carcinoma cell line A549.
Conversely, knockdown of LMP7 expression reduced sensitivity to carfilzomib in KCL22S and LAMA84S cells. These results suggest that both CT-L subunits are required for optimal effect and that proteasome composition may predict the response to carfilzomib.
In summary, this work shows that carfilzomib effectively reduces proliferation and induces apoptosis in CML cell lines and primary cells, regardless of their sensitivity to imatinib. We have shown for the first time that proteasome inhibition in CML cells is associated with a decrease in ERK signaling and increased expression of the tumor suppressor ABI-2. Combination of carfilzomib with TKIs has been demonstrated to generate synergistic effects, even in imatinib-resistant cells, and the presence of immunoproteasome subunits influences sensitivity to carfilzomib. Taken together, these findings suggest that carfilzomib could be a useful therapeutic agent in CML, and its role in resensitizing imatinib-resistant cells to TKIs warrants further investigation.
MATERIALS AND METHODS Compounds
Imatinib and nilotinib were provided by Novartis Pharmaceuticals (Surrey, UK) and reconstituted in sterile water or DMSO, respectively. Carfilzomib was provided by Onyx Pharmaceuticals, Inc (South San Francisco, CA, USA) and was reconstituted in DMSO.
Cells and culture conditions
A number of cell lines were used to reflect a spectrum of imatinib-sensitive and -resistant disease. Ba/F3 cells transfected with p210 and mutated (T315I, M351T, H396P) BCR-ABL were kindly provided by Dr. Brian Druker, (Oregon Health and Science University, Portland, OR, USA). K562 cells were purchased from the European Collection of Cell Cultures (Salisbury, UK). LAMA84 imatinib-sensitive and -resistant clones (LAMA84S and LAMA84R) and KCL22 imatinib-sensitive and -resistant clones (KCL22S and KCL22R) were provided by Professor Junia Melo. LAMA84R cells have increased copy numbers of BCR-ABL and express the multidrug resistance p-glycoprotein 4 and the mechanism of resistance in KCL22R cells is independent of BCR-ABL. 41 Cells were cultured in a humidified incubator at 37 1C and 5% CO 2 in RPMI-1640 supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf serum (Gibco BRL, Paisley, UK). LAMA84R and KCL22R cell lines were cultured continuously in the presence of 1 mM imatinib. A549 lung carcinoma cells (European Collection of Cell Cultures) were cultured in DMEM supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf serum. Authentication was conducted by LGC Standards Cell Line Authentication Service.
Primary CML samples and normal controls Leukapheresis products were obtained from CML patients at the time of diagnosis and bone marrow from healthy donors was collected as a normal control. All samples were obtained with ethical approval from the Research Ethics Committee, Northern Ireland, and the National Health Service Greater Glasgow Institutional Review Board and those involved gave their informed consent in accordance with the Declaration of Helsinki. CD34 þ cells were enriched from the samples using an AutoMACS system according to the manufacturer's instructions (Miltenyi Biotech, Surrey, UK). CD34 þ cells were stained with CD34-APC and CD38 À FITC (BD Biosciences, Oxford, UK) and sorted using a FACSAria (BD Biosciences) to obtain an enriched CD34 þ 38 À population. CD34 þ and CD34 þ 38 À cells were cultured in IMDM medium (Gibco BRL) supplemented with serum substitute (bovine serum albumin, insulin, transferrin; StemCell Technologies, Grenoble, France), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mM 2-mercaptoethanol and 0.8 mg/ml low-density lipoprotein (all from Sigma-Aldrich, Dorset, UK) and a growth factor cocktail of 20 ng/ml recombinant human (rh) IL-3, 20 ng/ml rhIL-6, 100 ng/ ml rh Flt-3 ligand and 100 ng/ml rh stem cell factor (all from StemCell Technologies).
Long-term culture initiating cell assay CD34 þ cells were overlaid on a pre-established irradiated (80 Gy) stromal layer of M2-10B4 cells (ATCC, Middlesex, UK) in Myelocult myeloid longterm culture medium (StemCell Technologies). Cultures were maintained for 5 weeks with weekly half-medium changes. Cells were then harvested, counted and transferred to Methocult media (StemCell Technologies). After 2 weeks, colonies were counted using a light microscope.
Cell viability
CellTiter-Glo luminescent assay (Promega, Southampton, UK) was used to analyze cell viability by measuring ATP levels according to the manufacturer's instructions. Luminescence was measured using a Tecan Genios microplate reader (Tecan Genios, Reading, UK).
Cell proliferation
CyQUANT proliferation assay (Life Technologies, Paisley, UK) was used to analyze cell proliferation by measuring cellular DNA content using a fluorescent dye, according to the manufacturer's instructions. Fluorescence was measured using a Cytofluor Series 400 multiwell plate reader at an excitation wavelength of 480 nM and emission wavelength of 520 nM.
Cell cycle analysis
Cells were harvested, washed in phosphate-buffered saline and fixed in 70% ethanol. Fixed cells were stained with 50 mg/ml propidium iodide (Sigma) for 30 min. DNA content was subsequently measured using an LSR II flow cytometer.
Caspase-3 activity
The Caspase-Glo 3 Assay (Promega) was used to determine caspase-3 activity by measuring cleavage of DEVD, according to the manufacturer's instructions. Luminescence was measured using a Tecan Genios microplate reader.
Western blotting
Cells were harvested and lysed in radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors. Immunoprecipitation experiments were carried out using a crosslink immunoprecipitation kit (Pierce, Thermo Scientific, Loughborough, UK), according to the manufacturer's instructions. Equal amounts of protein were denatured in LDS sample buffer (Invitrogen Ltd, Paisley, UK) at 95 1C for 5 min, resolved by SDS-PAGE on 10% Bis-Tris gels (Invitrogen Ltd) and subsequently transferred to a polyvinylidene fluoride membrane. Immunoblotting was carried out using antibodies against ubiquitin, phosphorylated (p)-ERK, ERK, p-PI3K, PI3K, p-STAT5, STAT5, p-CRKL, cleaved caspase-3, cleaved caspase-8, cleaved caspase-9 (all from Cell Signaling Technology, Hertfordshire, UK), TRIM32 and GAPDH (both from Abcam, Cambridge, UK) and ABI 1/2 (kindly provided by Dr. Karim Dib, Queen's University Belfast) or ABI-2 (Abcam) and secondary antibodies anti-mouse and anti-rabbit (DAKO, Stockport, UK). Blots were scanned into the AutoChemi System (UVP, Cambridge, UK) and densitometry analysis was performed using LabWorks 4.5 image acquisition and analysis software. Values obtained were corrected to loading controls and are expressed as a percentage of untreated controls. The average values for three replicate experiments are shown for each cell line.
ProCISE assay
A proteasome active site ELISA by name of ProCISE (Proteasome Constitutive/Immunoproteasome Subunit ELISA) was used to measure each proteasome subunit activity of the constitutive and immunoproteasome in homogenates of cell samples. This assay was performed as previously described in. 26 
Analysis of drug combinations
The median effect of Chou-Talalay was employed to analyze the effect of carfilzomib in combination with imatinib or nilotinib using Calcusyn software (Biosoft, Cambridge, UK). 42 The values used for the analysis were derived from cell viability as measured by CellTiter-Glo.
Inhibition of gene expression by siRNA K562, KCL22S or LAMA84S cells were nucleofected following the manufacturer's instructions using the Cell Line Nucleofector Kit V, program T-03 (Amaxa, Lonza, Castleford, UK) and either siRNA directed against BCR-ABL (5 0 -GCA GAG AGU UCA AAA GCC CUU-3 0 ), LMP7 (Silencer Select siRNA ID s11360, Life Technologies) or a scrambled siRNA sequence (5 0 -UUG UAC GGC AUC AGC GUU ATT-3 0 ).
